• Neurocrine Biosciences announced published expert perspectives in Orphanet Journal of Rare Diseases on managing hyperphagia in Prader-Willi syndrome.
• Experts identified VYKAT XR, the first FDA-approved treatment for hyperphagia in PWS, as an important complement to behavioral and environmental support.
• The publication supports multidisciplinary care throughout patients’ lives, with broader assessments to capture symptoms that structured environments may mask.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610221605PR_NEWS_USPR_____LA78580) on October 22, 2026, and is solely responsible for the information contained therein.